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 PLAIN LANGUAGE SUMMARY 
 
 
Key message: In 2008, legal measures were introduced in the UK to manage the 
misuse of medicines containing pseudoephedrine or ephedrine. A review of evidence 
conducted in 2012 shows that the measures are continuing to effectively manage the 
risk of misuse of these medicines. 
 
 
Background 
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government 
agency responsible for regulating medicines and medical devices in the UK. We 
continually review the safety of medicines and vaccines in the UK, and inform 
healthcare professionals and the public of the latest updates through several means, 
including public assessment reports.  
 
The following report presents the 2012 review of the impact of measures introduced to 
control the potential misuse of medicines containing pseudoephedrine (PSE), or 
ephedrine (EPH), in the manufacture of the Class A controlled drug 
methylamphetamine. These measures were introduced in 2007–2008, and their impact 
has been reviewed yearly. 
 
PSE and EPH are nasal decongestantsa contained in many cough and cold medicines 
sold over-the-counter (OTC) in UK pharmacies. There is concern that PSE and EPH 
can be extracted from these medicines and used in the illegal manufacture of the Class 
A controlled drug methylamphetamineb – a highly addictive drug which affects the 
central nervous system and can cause serious physical and psychological harm. This 
concern prompted a public consultation in 2007, following which the Commission on 
Human Medicinesc (CHM) advised that a number of measures should be introduced to 
control the supply of OTC medicines containing PSE and EPH. These measures 
included reducing the pack size for OTC products containing PSE and EPH, and a 
restriction on sale to one pack per transaction. 
 
The CHM also advised that a Working Group should be set up to monitor the 
effectiveness of the pharmacy controls, and to advise the CHM on other measures that 
could be put in place to minimise the misuse of OTC medicines containing PSE or 
EPH. The Working Group was established in September 2007. Based on 
recommendations from CHM, legal sales restrictions were put in place in the UK on 
April 1st 2008 which made it illegal to sell or supply: 
 
• any product that contains more than 720 mg PSE or 180 mg EPH without a 
prescription  
• a combination of products that between them add up to more than 720 mg PSE 
or 180 mg EPH without a prescription 
• a product that contains PSE and a product that contains EPH in one transaction 
 
In addition, the Royal Pharmaceutical Society (RPS), formerly known as the Royal 
Pharmaceutical Society of Great Britain, issued guidance that the sale and supply of 
products containing PSE or EPH must only be carried out by pharmacists or suitably 
trained pharmacy staff under the supervision of a pharmacist. 
 
                                                 
a Drugs which help to clear a blocked nose 
b Commonly known as ‘methamphetamine’, ‘crystal meth’ or ‘ice’ 
c An independent body which gives advice to UK government Ministers about the safety, quality, and 
efficacy of medicines 
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Impact of restrictions and CHM recommendations 
 
Each year from 2009, the CHM has reviewed the evidence of the impact of these 
measures to control the misuse of PSE or EPH-containing medicines. Three public 
assessment reports giving full details of the evidence, and the CHM’s conclusions are 
available on our website: Controlling the risk of misuse of medicines containing 
pseudoephedrine and ephedrine, Pseudoephedrine and ephedrine: managing the risk 
of misuse of medicines – July 2010 update and Pseudoephedrine- and ephedrine-
containing medicines: 2011 review of actions to manage the risk of misuse. The 
evidence presented in these reports showed that the measures were helping to contain 
the potential problem of misuse, and that the sale of PSE and EPH products had 
reduced.  
 
Stakeholders including the pharmacy profession, the General Pharmaceutical Council 
(GPhC)a, the Home Office, the Association of Chief Police Officers (ACPO) and the 
Serious Organised Crime Agency (SOCA) have continued to take measures to 
minimise the misuse of medicines containing PSE and EPH. They report that these 
measures are continuing to be successful, and, for our 2012 review, have recently 
provided updated information on the impact of these measures, such as: 
 
• The RPS, the Pharmaceutical Society of Northern Ireland (PSNI), the National 
Pharmacy Association (NPA), the Company Chemists Association (CCA) and 
the Proprietary Association of Great Britain (PAGB) continue to raise and 
maintain awareness in the pharmacy profession of the indirect abuse potential 
of medicines containing PSE or EPH. 
 
• In a survey conducted in June 2011 of 409 NPA members, over 97% were 
aware of the rules regarding sales of PSE. This level of awareness is 
unchanged from last year. 
 
• Sales figures provided by the PAGB show that wholesale purchases of PSE 
products by pharmacies were stable from April 2010 to March 2011.  
 
The ACPO have reported only one incidence of small-scale manufacture of 
methylamphetamine. There was no evidence that this one report was indicative of a 
trend.  
 
The number of registered methylamphetamine addicts remains small. The ACPO’s 
assessment, based on findings to date, is that there is little to suggest a problem with 
methylamphetamine misuse across the UK. 
 
 
Conclusions 
 
In July 2012, the CHM considered the above feedback from stakeholders and 
concluded that the regulatory measures implemented in 2009 and 2010 to manage the 
risk of misuse of OTC medicines containing PSE or EPH were continuing to be 
effective. The CHM recommended that:  
 
• the present levels of monitoring, education and awareness measures by 
pharmacists should be maintained 
 
                                                 
a The regulatory body for pharmacists, pharmacy technicians and pharmacy premises in the UK 
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• liaison with stakeholders including the Home Office, the Association of Chief 
Police Officers (ACPO) and the Serious Organised Crime Agency (SOCA) 
should continue 
 
• a Working Group should be established as necessary to review the situation if 
any new concerns arisea.  
 
• MHRA should continue to monitor the situation and report only significant 
adverse changes to CHM.   
 
We thank the pharmacy profession for their substantial contribution to managing the 
risk of misuse of these products. 
                                                 
a Please note that the majority of the members of the original 2007 Working Group are no longer 
members of the CHM 
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 1. INTRODUCTION 
(See glossary for explanation of terms used in this report) 
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government 
agency responsible for regulating medicines and medical devices in the UK. We 
continually review the safety of all medicines in the UK and inform healthcare 
professionals and the public of the latest updates. The following report summarises the 
latest review of the impact of measures introduced to control potential misuse of 
medicines that contain pseudoephedrine (PSE)) or ephedrine (EPH), in the 
manufacture of the Class A controlled drug methylamphetamine. 
 
 
 
2. BACKGROUND 
 
PSE and EPH are nasal decongestants contained in many cough and cold medicines 
sold OTC in UK pharmacies. There has been increasing concern that PSE and EPH 
can be extracted relatively easily from over-the-counter (OTC) medicines and used in 
the illicit manufacture of methylamphetamine (colloquially known as 
‘methamphetamine’, ‘crystal meth’ or ‘ice’). Methylamphetamine was classified on 18 
January 2007 by the Home Office as a Class A controlled drug, based on the 
recommendation of the Advisory Council on the Misuse of Drugsa (ACMD).  
 
Because of this concern, a public consultation was carried out in March 2007 on 
minimising the risk of misuse of medicines containing PSE or EPH in the manufacture 
of methylamphetamine. In this consultation, the MHRA sought views on restricting the 
availability of these medicines by changing their legal status from pharmacy (P) to 
prescription-only medicines (POM), together with a restriction in their pack size.  
 
In July 2007, the Commission on Human Medicines (CHM; an independent body who 
give advice to UK government Ministers about the safety, quality, and efficacy of 
medicines) considered the responses to the consultation. They advised that the legal 
status of medicines containing (PSE) and ephedrine (EPH) should be reclassified from 
P to POM in July 2009, unless the risk of misuse of these OTC medicines in the illicit 
manufacture of methylamphetamine was contained. The CHM provided advice on pack 
size restrictions and other measures to control supply of OTC medicines containing 
PSE and EPH, and advised that a Working Group should be set up to advise on 
implementation of the measures (see press release and weblinked minutes).  
 
Accordingly, the CHM Working Group on PSE and EPH (Working Group) was 
established in September 2007 to advise the CHM on the implementation of measures 
that should be put in place to minimise the misuse of OTC medicines containing PSE 
or EPH in the illicit manufacture of methylamphetamine.  
 
Following CHM advice to restrict pack sizes of PSE and EPH, a further public 
consultation in October 2007 considered specific amendments to the Prescription Only 
Medicines Order 1997 (POM Order) to make the sale and supply of products 
containing more than 720 mg of PSE or 180 mg EPH prescription-only. This legislation 
came into force in the UK on 1st April 2008, after which it became illegal to sell or 
supply: 
 
• any product that contains more than 720 mg PSE or 180 mg EPH without a 
prescription. 
• a combination of products that between them add up to more than 720 mg PSE 
or 180 mg EPH without a prescription 
                                                 
a An independent expert body that advises the government on drug-related issues in the UK 
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• a product that contains PSE and a product that contains EPH in one 
transaction  
 
Professional guidance was also issued by the Royal Pharmaceutical Society [RPS], 
formerly known as the Royal Pharmaceutical Society of Great Britain (RPSGB), for 
PSE or EPH-containing products to be supplied personally by a pharmacist or a trained 
staff member under the supervision of a pharmacist (see section 3.1 below). 
 
In July 2009, July 2010, and again in July 2011, the CHM considered the impact of 
measures which had been put in place to minimise the risk of misuse of PSE and EPH-
containing products and recommended that: the existing levels of monitoring, education 
and awareness measures by pharmacists should be maintained; liaison with 
stakeholders including the Home Office (HO), Association of Chief Police Officers 
(ACPO) and the Serious Organised Crime Agency (SOCA) should continue; the 
Working Group should be reconstituted as necessary, and in any case to review the 
situation on a yearly basis.  
 
Three public assessment reports published in July 2009, July 2010 and September 
2011 giving full details of the evidence and the CHM’s conclusions are available on our 
website: Controlling the risk of misuse of medicines containing pseudoephedrine and 
ephedrine, Pseudoephedrine and ephedrine: managing the risk of misuse of medicines 
– July 2010 update and Pseudoephedrine- and ephedrine-containing medicines: 2011 
review of actions to manage the risk of misuse. Articles on this issue were also 
published in the September 2009, September 2010 and September 2011 editions of 
Drug Safety Update, the MHRA monthly bulletin for health professionals on the safety 
of medicines. 
 
 
 
3. UPDATE ON IMPLEMENTATION OF MEASURES 
 
In light of the CHM’s recommendations above, stakeholders have continued to take 
measures to help minimise the misuse of OTC medicines containing PSE or EPH in the 
illicit manufacture of methylamphetamine. Information provided recently is summarised 
below. 
 
3.1  Pharmacy supervision plus education and awareness initiatives 
 
Close links have been maintained with the RPS, the Pharmaceutical Society of 
Northern Ireland (PSNI) the National Pharmacy Association (NPA) the Company 
Chemists Association (CCA) and the Proprietary Association of Great Britain (PAGB). 
These organisations have provided updated information to the MHRA on the continuing 
measures to maintain awareness by the pharmacy profession of the indirect abuse 
potential of medicines containing PSE or EPH. 
 
The RPS is committed to supporting pharmacists in relation to the misuse of PSE or 
EPH and issues regular communications to members to ensure they maintain vigilance 
with these products. These include a ‘Look, Listen and Report your suspicions’ guide 
and advice on “Supplying over-the-counter analgesics” and “Dealing with requests for 
large quantities of medicines over-the-counter”.  
 
The PSNI has placed guidance on its website relating to PSE sales. Monitoring the 
website shows there is constant access of this information by either professionals or 
the public. The PSNI liaises with the Northern Ireland Department of Health, Social 
Services and Public Safety (DHSSPS) and its pharmaceutical inspectorate, and they 
report no evidence of misuse or abuse of PSE/EPH containing products to date in 
Northern Ireland.  
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The NPA continues to maintain and develop an awareness training resource for 
members to download from the NPA website. It is now available in various formats to 
suit the users, eg, group training or individual learner, and also for use with an MP3 
player. Through regular NPA promotion, eg, via superintendant email alerts and the 
NPA member magazine, pharmacists are encouraged to record staff training as part of 
an audit trail; in particular, newly appointed staff are made aware of the current rules. In 
a survey conducted in May 2012 of 409 members, over 97% of members responded 
that they are aware of the rules regarding sales of PSE-containing products. Training 
packs will be sent to those members who responded that were not aware of these 
rules. The NPA are reassured by the high level of awareness, which remains 
unchanged from last year. 
 
The CCA continues to operate the MethGuard UK awareness training programme. The 
vast majority of members have however developed their own in-house resource, 
including several major high-street pharmacy stores. Companies report that awareness 
training on the rules regarding sales of products containing PSE or EPH is part of the 
standard training for all relevant staff (eg, medicines counter assistants) and new staff. 
Some companies provide refresher training prior to the autumn/winter cough and cold 
season, and audit compliance through different schemes (eg, a mystery shopper 
scheme). 
 
3.2  Pharmacy reporting of suspicions 
 
The ‘Look, Listen and Report your suspicions’ guide is available to members on the 
RPS website. The GPhC are not aware of any cases of pharmacists reporting the 
inappropriate sale of PSE or EPH products over the last year, nor of any reports of 
suspicious behaviour. They report that pharmacists are aware and alert to the potential 
abuse of products containing these medicines. 
 
3.3 Sales monitoring for evidence of use of over-the-counter medicines in the 
manufacture of methylamphetamine 
 
The PAGB provided wholesale figures for PSE and EPH products. The figures show a 
decline in wholesale purchases by pharmacies, of 1.6% and 19.2%, respectively, 
during the financial year April 2011–March 2012. The manufacturers of brand leader 
products have reported a small increase of 0.6 – 1.3% in sales of PSE-containing 
products; this would indicate that PSE sales appear to have reached a plateau 
following significant reductions in previous years.  Some branded products have been 
discontinued.  
 
3.4  Triggers for a review of the availability of pseudoephedrine or ephedrine 
over-the-counter medicines 
 
The CHM has previously agreed a number of factors which act as potential triggers for 
a review of the pharmacy/OTC availability of PSE or EPH-containing medicines. The 
ACPO, SOCA and the Home Office have provided updated information in these areas 
which is summarised below: 
 
The ACPO reported one incidence of a small-scale manufacture of 
methylamphetamine, although a link to use of PSE or EPH products has not been 
confirmed.  
 
Reports of suspicious requests for OTC PSE or EPH-containing medicines by 
pharmacists to RPSGB/SOCA are documented via the reporting system (the ‘Look, 
Listen and Report your suspicions’ guide). Over 2011 – 2012, there have been no 
pharmacy suspicion reports of customers behaving suspiciously when attempting to 
purchase quantities of PSE or EPH. Data from the last five years do not indicate a 
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significant increase in the number of methylamphetamine users, and the numbers of 
registered methylamphetamine addicts remains smalla.  
 
There have been no other reports of concern from ACPO or SOCA regarding misuse of 
PSE or EPH products. Based on findings to date, the ACPO considers there is very 
little evidence of a problem with methylamphetamine misuse across the UK but they 
continue to monitor the situation.  
 
Liaison with relevant stakeholders including ACPO, SOCA, and the GPhC Pharmacy 
inspectorate will continue to provide suitable information as it arises. Overall, SOCA 
and ACPO are aware of the potential dangers of misuse, but at present the indications 
are that misuse of medicines in relation to methamphetamine production is still not 
presenting any major problems. They consider that the current restrictions on OTC 
medicines containing PSE or EPH are sufficient to address the risk of potential misuse 
and abuse. 
 
 
 
4. INTERNATIONAL POSITION   
 
An update of available information on measures implemented in other countries to 
minimise the risk of misuse of PSE or EPH-containing medicines is provided below. 
 
USA 
The situation is stable and there have been no new developments in the marketing of 
PSE in the USA. It is sold OTC (behind-the-counter) unless individual state laws dictate 
otherwise where there is legislation that restricts PSE to prescription status.  
 
 
New Zealand  
 
In 2011, the Government introduced new legislation making ephedrine and 
pseudoephedrine Class B1 drugs under the Misuse of Drugs Act as part of a range of 
initiatives targeted on reducing methamphetamine manufacture and abuse. Since then 
the number of clan labs identified by police and the number of crimes associated with 
methamphetamine has reduced; although there is no way to link the reduction in 
manufacture with the decision to reclassify PSE and EPH. As the market had already 
moved to phenylephrine ahead of the legislation change there has effectively been two 
full winters where all cough and cold products on the market were free of PSE without 
major consumer complaint or question.   
 
 
 
5. DISCUSSION 
 
The feedback from stakeholders is that the regulatory measures recommended by the 
CHM to help manage the risk of misuse of OTC medicines containing PSE or EPH are 
continuing to be implemented effectively. There was one incidence of small scale 
manufacture of methylamphetamine. There is no evidence from ACPO that this case is 
indicative of a trend which requires additional measures to control the misuse of PSE-
containing products.  
 
The pharmacy representative organisations are maintaining their support and 
encouragement of education and training by pharmacists and pharmacy staff, to 
                                                 
a Data from the  British Crime Survey 2010 – 2011 and the National Treatment Agency
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ensure awareness of misuse of PSE and EPH and the links to methylamphetamine 
misuse. 
 
There have been no reports from pharmacies of suspicious requests for unusual 
quantities of OTC PSE.  
 
The factors that would trigger a review of continued OTC PSE or EPH availability have 
been reviewed and there are no significant issues of concern.  
 
Other countries are also taking steps to better manage the risk of misuse of PSE and 
EPH products. 
 
 
 
6. RECOMMENDATIONS AND CONCLUSIONS  
 
After reviewing the updated information summarised in this report, the CHM agreed 
that the measures implemented in 2007 and reviewed yearly since then are continuing 
to control the supply of OTC products containing PSE or EPH. The CHM 
recommended that:  
 
• the present level of monitoring and the education and awareness measures by 
pharmacists should be maintained 
 
• liaison with stakeholders including the Home Office, ACPO and SOCA should 
continue 
 
• a Working Group should be established as necessary to review the situation if any 
new concerns arisea.  
 
• MHRA should continue to monitor the situation and report only significant adverse 
changes to CHM.  
 
 
We thank the pharmacy profession for their substantial contribution to managing the 
risk of misuse of these products. 
 
.
                                                 
a Please note that the majority of the members of the original 2007 Working Group are no longer 
members of the CHM 
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 7. GLOSSARY 
 
Class A controlled drugs 
In the UK, certain drugs are designated as controlled substances (ie, only certain 
designated persons may manufacture, supply and possess them) and are divided into 
three classes: A, B and C. Those categorised as Class A are considered to be the most 
likely to cause harm (see 
http://webarchive.nationalarchives.gov.uk/20100419081707/http:/drugs.homeoffice.gov
.uk/drugs-laws/misuse-of-drugs-act/ for more information) 
 
Clinical Audit 
A process performed by the UK’s National Health Service that seeks to improve patient 
care and outcomes by reviewing performance in the Service 
 
Decongestant 
A drug that helps to clear a blocked nose 
 
Ephedrine 
A drug that narrows blood vessels and widens airways, used mainly as a nasal 
decongestant 
 
Illicit 
Illegal 
 
Legislation 
A proposed law or group of laws 
 
Methylamphetamine 
A Class A controlled drug that is illegal to possess, supply or manufacture. It is a 
stimulant that causes feelings of exhilaration 
 
Misuse (of medicines) 
Using a drug for improper purposes (ie, not for treating a condition or disease)  
 
Over-the-counter 
Medicines that can be sold to a customer without a prescription 
 
Pharmacy (referring to medicine classification) 
Medicines that can only be sold to a customer by a trained pharmacist 
 
Phenylephrine 
A drug that narrows blood vessels, used mainly as a nasal decongestant 
 
Precursor (chemical) 
A chemical that is required in the process of making a drug, which becomes part of the 
end-product 
 
Prescription Only Medicine 
Medicines that can only be sold to a customer if they have a valid prescription from a 
doctor 
 
Pseudoephedrine 
A drug that narrows blood vessels, used as a nasal decongestant 
 
Public Consultation 
A process that seeks the public’s input on matters that affect them 
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Stakeholders 
A person, group, organisation or system which affects, or can be affected by, an 
organisation’s actions 
 
Stimulant 
A substance that causes increased activity in the body, particularly in the nervous 
system, and the heart and circulatory system 
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